Our studies may provide a novel therapeutic strategy for recurrence, advanced PCa, CRPC, which failed the both traditional (e.g., LHRH agonist, AR blocker) and latest (e.g., acetate abirateron, enzalutamide) forms of hormonal therapy. The gene discussed is GNRH1; the disease is posterior cortical atrophy.